COVID-19 Vaccine effectiveness against symptomatic infection and hospitalization in Belgium, July 2021-APRIL 2022

Toon Braeye, Joris van Loenhout, Ruben Brondeel, Veerle Stouten, Pierre Hubin, Matthieu Billuart, Jenny Chung, Mathil Vandromme, Chloé Wyndham-Thomas, Koen Blot, Lucy Catteau
doi: https://doi.org/10.1101/2022.05.09.22274623

Article Information

doi 
https://doi.org/10.1101/2022.05.09.22274623
History 
  • May 11, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Toon Braeye, MD1,*,
  2. Joris van Loenhout, PhD1,
  3. Ruben Brondeel, PhD1,
  4. Veerle Stouten, PhD1,
  5. Pierre Hubin, PhD1,
  6. Matthieu Billuart, MSc1,
  7. Jenny Chung, PhD1,
  8. Mathil Vandromme, PhD1,
  9. Chloé Wyndham-Thomas, PhD1,
  10. Koen Blot, PhD1 and
  11. Lucy Catteau, PhD1
  1. 1Department of Epidemiology and public health, Sciensano, Juliette Wytsmansstraat 14, 1000, Brussel, Belgium
  1. ↵*Corresponding author; email: toon.braeye{at}sciensano.be
Back to top
Posted May 11, 2022.
Download PDF
Data/Code
Email
COVID-19 Vaccine effectiveness against symptomatic infection and hospitalization in Belgium, July 2021-APRIL 2022
Toon Braeye, Joris van Loenhout, Ruben Brondeel, Veerle Stouten, Pierre Hubin, Matthieu Billuart, Jenny Chung, Mathil Vandromme, Chloé Wyndham-Thomas, Koen Blot, Lucy Catteau
medRxiv 2022.05.09.22274623; doi: https://doi.org/10.1101/2022.05.09.22274623
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area